Abstract
Obesity is a highly prevalent disease with multiple implications for cardiovascular morbidity and mortality. The traditional view of obesity is that excessive adipose tissue represents a passive storage depot of excess energy. However, obesity has been demonstrated to be a highly active endocrine organ with multiple metabolic pathways that interact with classic cardiac risk factors. The role of inflammation in atherosclerosis has been clarified by the ready availability of a variety of markers, including C-reactive protein, adiponectin, tumor necrosis factor-α, hemostatic markers, resistin, and a variety of emerging markers such as interleukins and adhesion molecules. Adipose tissue has been demonstrated to be the site of synthesis of a variety of proteins that are intimately involved in the regulation of inflammation. The concept that obesity represents an inflammatory state has gained credence over the past decade and has provided insights into the mechanisms of atherosclerosis and risk factor interaction.
Similar content being viewed by others
References and Recommended Reading
Mokdad AH, Ford ES, Bowman BA, et al.: The continuing increase of diabetes in the US. Diabetes Care 2001, 24:412.
Rashid MN, Fuentes F, Touchon RC, Wehner PS: Obesity and the risk for cardiovascular disease. Prev Cardiol 2003, 6:42–47.
Ogden CL, Carroll MD, Curtin LR, et al.: Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006, 295:1549–1555.
Hu FB, Willett WC, Li T, et al.: Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004, 351:2694–703.
Grundy SM, Cleeman JI, Daniels SR, et al.: American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.
Stern MP: Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes 1995, 44:369–374.
Moshage HJ, Roelofs HM, van Pelt JF, et al.: The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988, 155:112–117.
Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004, 44:6–11.
Devaraj S, Du Clos TW, Jialal I: Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005, 25:1359–1363.
Verma S, Devaraj S, Jialal I: Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006, 113:2135–2150; discussion 2150.
Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363–369.
Jialal I, Devaraj S: Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001, 116(Suppl):S108–S115.
Muntner P, He J, Chen J, et al.: Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004, 14:686–695.
Clement K, Viguerie N, Poitou C, et al.: Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004, 18:1657–1669.
Halaas JL, et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543–546.
Munzberg H, Flier JS, Bjorbaek C: Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 2004, 145:4880–4889.
Wannamethee SG, Tchernova J, Whincup P, et al.: Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 2006, In press.
Dunajska K, Milewicz A, Jedrzejuk D, et al.: Plasma adiponectin concentration in relation to severity of coronary atherosclerosis and cardiovascular risk factors in middle-aged men. Endocrine 2004, 25:215–221.
Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941–946.
Arita Y, Kihara S, Ouchi N, et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79–83.
Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473–2476.
Shibata R, Ouchi N, Kihara S, et al.: Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 2004, 279:28670–28674.
Kern PA, Ranganathan S, Li C, et al.: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745–E751.
Hotamisligil GS, Arner P, Caro JF, et al.: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409–2415.
Moller DE: Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000, 11:212–217.
Avellone G, Avellone G, Di Garbo V, et al.: Evaluation of cardiovascular risk factors in overweight and obese subjects. Int Angiol 1994, 13:25–29.
Mertens I, Van Gaal LF: Visceral fat as a determinant of fibrinolysis and hemostasis. Semin Vasc Med 2005, 5:48–55.
Palomo I, Alarcon M, Moore-Carrasco R, Argiles JM: Hemostasis alterations in metabolic syndrome (review). Int J Mol Med 2006, 18:969–974.
Steppan CM, Lazar MA: The current biology of resistin. J Intern Med 2004, 255:439–447.
McTernan PG, Kusminski CM, Kumar S: Resistin. Curr Opin Lipidol 2006, 17:170–175.
Patel L, Buckels AC, Kinghorn IJ, et al.: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472–476.
Shetty GK, Economides PA, Horton ES, et al.: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004, 27:2450–2457.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mehta, S., Farmer, J.A. Obesity and inflammation: A new look at an old problem. Curr Atheroscler Rep 9, 134–138 (2007). https://doi.org/10.1007/s11883-007-0009-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11883-007-0009-4